How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors'associated rash?

International Journal of Dermatology

Volumn 47, Issue 11, 2008, Pages 1203-1204

  Cholongitas, Evangelos ^a   Kokolakis, George ^a   Ioannidou, Despina ^a  

^a General Hospital of Sitia   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DOCETAXEL; DOXYCYCLINE; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PIPERACILLIN PLUS TAZOBACTAM;

ABSENCE OF SIDE EFFECTS; ACNE; ADULT; ANAMNESIS; BACTERIAL INFECTION; BACTERIUM CULTURE; BRAIN METASTASIS; CASE REPORT; CLINICAL FEATURE; COMEDO; CULTURE TECHNIQUE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; PUS; SERRATIA MARCESCENS;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERRATIA INFECTIONS; SERRATIA MARCESCENS; SUPPURATION;

EID: 55449126474     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03691.x     Document Type: Letter

References (7)

1. Perez-Soler R. HER1/EGFR targeting: Refining the strategy. Oncologist 2004; 9: 58-67.
2. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29 (5 Suppl. 14): 38-44.
3. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
4. Agero AL, Dusza SW, Venuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-670.
5. Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs 2006; 22: 152-162.
6. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 2003; 17 (11 Suppl. 12): 23-28.
7. Zoller A, Schäd SG, Gross GE. Erlotinib-associated skin reactions - case report and proposal for classification. Br J Dermatol 2006; 155: 1293-1295.